EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study

Yi Jiang, Ke Su, Han Li, Chenjie Wang, Zhenying Wu, Jiali Chen, Zhiyao Zhang, Kun He, Yunwei Han

Investigational New Drugs · 17.12.2024

DOI: 10.1007/s10637-024-01468-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Investigational New Drugs, online erschienen am 17.12.2024. Verfasst von Yi Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou City, Sichuan Province, 646000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Project of Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, therapeutic combinations of immune checkpoint inhibitors (ICIs) with anti-angiogenic agents have shown promising outcomes and have the potential to establish a new standard of care. The efficacy and safety of the first-line combination of envafolimab (an ICI) and lenvatinib (an anti-tumor angiogenesis drug) for the treatment of patients with inoperable hepatocellular carcinoma (HCC) have not been demonstrated. Unresectable HCC patients with an Eastern Cooperative Oncology Group (ECOG) physical status score ≤ 1 and a Child-Pugh score ≤ 7 who had not received systemic therapy were included in this single-arm, exploratory, multicentre phase II clinical study. All patients were required to meet the criteria of being at least 18 years of age, having no history of other malignancies, and existing at least one measurable lesion. The patients were treated with envafolimab (150 mg, QW, subcutaneous) in combination with lenvatinib (12 mg for patients weighing over 60 kg, 8 mg for patients weighing under 60 kg). The co-primary endpoint of the study was overall survival (OS), while surrogate endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Between March 2022 and April 2023, 36 patients were enrolled, 30 of whom were treated with envafolimab plus lenvatinib. At data cutoff, the median follow-up duration was 20 months (95% CI 18.9-21.1). Among the 30 assessable patients (patients treated according to the trial protocol), the median overall survival (mOS) and median progression-free survival (mPFS) for the therapy comprising envafolimab alongside lenvatinib were 18.5 months (95% CI 13.2-23.8) and 9.4 months (95% CI 1.6-15.6), respectively. The ORR and the DCR (evaluated according to mRECIST criteria) reached 40% and 80%, respectively. In terms of safety, 23 patients (76.7%) experienced at least one treatment-related adverse event (TRAE), of which the most common was elevated aspartate aminotransferase (AST, 23.3%). Furthermore, grade 3 and higher TRAEs occurred in 30%. This study demonstrates that envafolimab in combination with lenvatinib exhibits favourable anti-cancer activity and a manageable safety profile for the first-line treatment of patients with unresectable HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

EfficacyEnvafolimabHepatocellular carcinomaLenvatinibSafety

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou City, Sichuan Province, 646000, China.
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100000, China.
  • Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou City, Sichuan Province, 646000, China. hktongji@swmu.edu.cn.
  • Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou City, Sichuan Province, 646000, China. Lanpaoxiansheng@126.com.

Förderung

  • the Project of Sichuan Science and Technology Program

Zitieren

APA

Jiang, Y., Su, K., Li, H., Wang, C., Wu, Z., Chen, J., Zhang, Z., He, K., & Han, Y. (2024). Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01468-6

Vancouver

Jiang Y, Su K, Li H, Wang C, Wu Z, Chen J, et al. Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01468-6

BibTeX
@article{Jiang2024,
  author = {Jiang, Yi and Su, Ke and Li, Han and Wang, Chenjie and Wu, Zhenying and Chen, Jiali and Zhang, Zhiyao and He, Kun and Han, Yunwei},
  title = {Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01468-6}
}
Kostenlos starten →